Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$31.22M+384.62%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David H. Dupuy
- Sector
- Real Estate
- Industry
- REIT - Healthcare Facilities
- Employees
- 35
- Beta
- 0.65
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 0.28
Financials
Revenue
$31.22M+384.6%Net Income
$2.36M+122.2%EBITDA
$22.23M+417.2%Free Cash Flow
$13.35M+287.2%EPS (diluted)
$0.06-27.0%Shares Outstanding (diluted)
27.02M+111.9%Operating Expenses
$4.89MCash & Debt
$2.67MReturn of Capital
$14.05MRevenue by Segment (annual)
$6.38MDividend per Share
$0.33Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $121.19M | $5.10M | $0.08 |
| 2024 | $115.79M | $-3.18M | $-0.23 |
| 2023 | $112.84M | $7.71M | $0.20 |
| 2022 | $97.68M | $22.02M | $0.81 |
| 2021 | $90.58M | $22.49M | $0.87 |
| 2020 | $75.68M | $19.08M | $0.80 |
| 2019 | $60.85M | $8.38M | $0.37 |
| 2018 | $48.63M | $4.40M | $0.25 |
| 2017 | $37.34M | $3.51M | $0.19 |
| 2016 | $25.20M | $2.72M | $0.24 |
| 2015 | $8.63M | $-1.46M | $-0.31 |
| 2014 | $18.73M | $7.58M | $1.13 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CHCT's reported EPS growth of -21.6% a year over 11 years. Historical EPS growth of -22% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.08
- Implied price
- $1.52
- Return from $13.15
- -35.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.75 — -94.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -25.0% | -47.2% | -44.8% | -42.7% | -40.9% | -39.3% |
| -20.0% | -43.7% | -41.1% | -38.9% | -37.0% | -35.3% |
| -15.0% | -40.1% | -37.4% | -35.1% | -33.0% | -31.2% |
| -10.0% | -36.6% | -33.7% | -31.3% | -29.1% | -27.2% |
| -5.0% | -33.1% | -30.0% | -27.4% | -25.2% | -23.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80-11.11%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·6h ago·Negative
Community Healthcare Trust: Cheap After Dividend Cut, But This 10% REIT Is A Hold Community Healthcare Trust cut its dividend by 31%, triggering a 28% stock decline and a current 10% yield. CHCT trades at a steep 40% discount to peers on AFFO/FFO multiples, reflecting elevated leverage and recent dividend uncertainty. Management redirected capital from dividends to acquisitions, targeting 60–65% AFFO payout and incremental AFFO growth of $0.06–$0.07/share annually.
View source ↗ - Newsprnewswire.com·6d ago·Neutral
Community Healthcare Trust Announces Third Quarter Earnings Release Date And Conference Call FRANKLIN, Tenn., Oct. 14, 2026 /PRNewswire/ -- Community Healthcare Trust Incorporated (NYSE: CHCT) today announced that on Tuesday evening, November 3, 2026, after the market closes, it will report results for the third quarter of 2026.
View source ↗ - Newsseekingalpha.com·72d ago·Negative
Community Healthcare Trust Is Still Overvalued Community Healthcare Trust (CHCT) remains overvalued at $15.58, with fair value estimated at $12 per share based on true AFFO analysis. CHCT faces headwinds from high lease rollovers, lower property quality, and tenant retention issues, pressuring future same-store NOI and requiring substantial tenant improvements. Resolution of six troubled behavioral health facilities is progressing, but new leases will likely reduce NOI while stabilizing risk.
View source ↗
Earnings
Tue, Nov 3(in 12 days)
Consensus estimate $0.09 per share
Typical surprise -55.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.06 vs $0.11miss
- Tue, May 5$0.07 vs $0.44miss
- Tue, Feb 17$0.55 vs $0.11beat
- Tue, Oct 28$0.03 vs $0.08miss
- Tue, Jul 29$-0.50 vs $0.08miss
- Tue, Apr 29$0.03 vs $0.07miss
Estimates and results for CHCT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CHCT officers and directors.
- Bought
- $1.3m
- Sold
- $51k
11 trades
1 trade
- Dupuy David H.bought
- Hensley Robert Zbought
- Cotman Cathrinebought
- Van Horn R. Lawrencebought
- Dupuy David H.bought
- Cotman Cathrinebought
- Cotman Cathrinesold
- Van Horn R. Lawrencebought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CHCT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.